Literature DB >> 33374273

N-terminal VP1 Truncations Favor T = 1 Norovirus-Like Particles.

Ronja Pogan1,2, Victor U Weiss3, Kevin Bond4, Jasmin Dülfer1, Christoph Krisp5, Nicholas Lyktey4, Jürgen Müller-Guhl1,6, Samuele Zoratto3, Günter Allmaier3, Martin F Jarrold4, Cesar Muñoz-Fontela6, Hartmut Schlüter5, Charlotte Uetrecht1,2.   

Abstract

Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Emerging genotypes, which are divided based on the sequence of the major capsid protein VP1, further enhance this public threat. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial for using virus-like particles (VLPs) for vaccine development. However, there is no vaccine available yet. Here, VLPs from different variants produced in insect cells were characterized in detail using a set of biophysical and structural tools. We used native mass spectrometry, gas-phase electrophoretic mobility molecular analysis, and proteomics to get clear insights into particle size, structure, and composition, as well as stability. Generally, noroviruses have been known to form mainly T = 3 particles. Importantly, we identified a major truncation in the capsid proteins as a likely cause for the formation of T = 1 particles. For vaccine development, particle production needs to be a reproducible, reliable process. Understanding the underlying processes in capsid size variation will help to produce particles of a defined capsid size presenting antigens consistent with intact virions. Next to vaccine production itself, this would be immensely beneficial for bio-/nano-technological approaches using viral particles as carriers or triggers for immunological reactions.

Entities:  

Keywords:  CDMS; capsid assembly; differential mobility analysis; nES GEMMA; native mass spectrometry; norovirus

Year:  2020        PMID: 33374273      PMCID: PMC7824077          DOI: 10.3390/vaccines9010008

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  54 in total

1.  Outbreak of gastroenteritis due to sapovirus.

Authors:  Grant S Hansman; Hiroyuki Saito; Chihiro Shibata; Shizuko Ishizuka; Mitsuaki Oseto; Tomoichiro Oka; Naokazu Takeda
Journal:  J Clin Microbiol       Date:  2007-01-31       Impact factor: 5.948

2.  Improving the performance of a quadrupole time-of-flight instrument for macromolecular mass spectrometry.

Authors:  Robert H H van den Heuvel; Esther van Duijn; Hortense Mazon; Silvia A Synowsky; Kristina Lorenzen; Cees Versluis; Stan J J Brouns; Dave Langridge; John van der Oost; John Hoyes; Albert J R Heck
Journal:  Anal Chem       Date:  2006-11-01       Impact factor: 6.986

3.  In-gel digestion for mass spectrometric characterization of proteins and proteomes.

Authors:  Andrej Shevchenko; Henrik Tomas; Jan Havlis; Jesper V Olsen; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Norwalk virus: how infectious is it?

Authors:  Peter F M Teunis; Christine L Moe; Pengbo Liu; Sara E Miller; Lisa Lindesmith; Ralph S Baric; Jacques Le Pendu; Rebecca L Calderon
Journal:  J Med Virol       Date:  2008-08       Impact factor: 2.327

5.  Charge detection mass spectrometry with resolved charge states.

Authors:  Nathan C Contino; Elizabeth E Pierson; David Z Keifer; Martin F Jarrold
Journal:  J Am Soc Mass Spectrom       Date:  2012-11-30       Impact factor: 3.109

Review 6.  Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Authors:  Ming Tan; Xi Jiang
Journal:  Nanomedicine (Lond)       Date:  2012-06       Impact factor: 5.307

7.  Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particles.

Authors:  Jessica M Devant; Götz Hofhaus; David Bhella; Grant S Hansman
Journal:  Antiviral Res       Date:  2019-05-27       Impact factor: 5.970

8.  Three-dimensional structure of baculovirus-expressed Norwalk virus capsids.

Authors:  B V Prasad; R Rothnagel; X Jiang; M K Estes
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Assembly of homogeneous norovirus-like particles accomplished by amino acid substitution.

Authors:  Yuichi Someya; Haruko Shirato; Kazuya Hasegawa; Takashi Kumasaka; Naokazu Takeda
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

10.  Virus-like particle size and molecular weight/mass determination applying gas-phase electrophoresis (native nES GEMMA).

Authors:  Victor U Weiss; Ronja Pogan; Samuele Zoratto; Kevin M Bond; Pascale Boulanger; Martin F Jarrold; Nicholas Lyktey; Dominik Pahl; Nicole Puffler; Mario Schelhaas; Ekaterina Selivanovitch; Charlotte Uetrecht; Günter Allmaier
Journal:  Anal Bioanal Chem       Date:  2019-07-06       Impact factor: 4.142

View more
  4 in total

1.  Molecular weight determination of adeno-associate virus serotype 8 virus-like particle either carrying or lacking genome via native nES gas-phase electrophoretic molecular mobility analysis and nESI QRTOF mass spectrometry.

Authors:  Samuele Zoratto; Victor U Weiss; Jerre van der Horst; Jan Commandeur; Carsten Buengener; Alexandra Foettinger-Vacha; Robert Pletzenauer; Michael Graninger; Guenter Allmaier
Journal:  J Mass Spectrom       Date:  2021-09-19       Impact factor: 2.394

Review 2.  Top-Down and Bottom-Up Proteomics Methods to Study RNA Virus Biology.

Authors:  Yogy Simanjuntak; Kira Schamoni-Kast; Alice Grün; Charlotte Uetrecht; Pietro Scaturro
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

Review 3.  Plant-based vaccines and antibodies to combat COVID-19: current status and prospects.

Authors:  Kuldeep Dhama; Senthilkumar Natesan; Mohd Iqbal Yatoo; Shailesh Kumar Patel; Ruchi Tiwari; Shailendra K Saxena; Harapan Harapan
Journal:  Hum Vaccin Immunother       Date:  2020-12-03       Impact factor: 3.452

4.  Norovirus-glycan interactions - how strong are they really?

Authors:  Thomas Peters; Robert Creutznacher; Thorben Maass; Alvaro Mallagaray; Patrick Ogrissek; Stefan Taube; Lars Thiede; Charlotte Uetrecht
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.